Study on the Chronic and Acute Effects of Nordic Berry Beverage on Cognitive Function
NCT05693441, Not applicable, Completed, Aventure AB
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Study on the Chronic and Acute Effects of Nordic Berry Beverage on Cognitive Function | ClinicalTrials.gov |
| NCT number | NCT05693441 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 62 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Aventure AB | ClinicalTrials.gov |
| Conditions | Age-related Cognitive Decline | ClinicalTrials.gov |
| Interventions | Active berry product, Reference berry-like product | ClinicalTrials.gov |
| First posted | 2023-01-23 | ClinicalTrials.gov |
| Last updated | 2023-07-06 | ClinicalTrials.gov |
Registered outcomes 45
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Cognitive measures-memory | Change from baseline following 12 weeks daily consumption, compared to control | Episodic memory - assessed using computerized cognitive battery including PAL (paired associates learning) test. | ClinicalTrials.gov |
| Primary | Cognitive measures-memory | Change from baseline following 12 weeks daily consumption, compared to control | Episodic memory - assessed using computerized cognitive battery including VRM (verbal recognition memory) test | ClinicalTrials.gov |
| Primary | Cognitive measures - memory | Change from baseline at 1.5 hours post-dose, and 12 weeks daily consumption, compared to control | Working memory - assessed using computerized cognitive battery including SWM (spatial working memory) test. | ClinicalTrials.gov |
| Primary | Cognitive measures - memory | Change from baseline at 1.5 hours post-dose, and 12 weeks daily consumption, compared to control | Working memory - assessed using computerized cognitive battery including SDPT (symbol digits processing test). | ClinicalTrials.gov |
| Primary | Cognitive measures - executive function | Change from baseline at 1.5 hours post-dose, and 12 weeks daily consumption, compared to control | Executive function - assessed using computerized cognitive battery including TMT (trail making test) A \& B. | ClinicalTrials.gov |
| Primary | Cognitive measures - executive function | Change from baseline at 1.5 hours post-dose, and 12 weeks daily consumption, compared to control | Executive function - assessed using computerized cognitive battery including PASAT (paced auditory serial addition test). | ClinicalTrials.gov |
| Primary | Cognitive measures - executive function | Change from baseline at 1.5 hours post-dose, and 12 weeks daily consumption, compared to control | Executive function - assessed using computerized cognitive battery including Stroop test. | ClinicalTrials.gov |
| Primary | Cognitive measures - executive function | Change from baseline at 1.5 hours post-dose, and 12 weeks daily consumption, compared to control | Executive function, verbal fluency - assessed using computerized cognitive battery including F-A-S test measuring word fluency | ClinicalTrials.gov |
| Primary | Cognitive measures - attention | Change from baseline at 1.5 hours post-dose, and 12 weeks daily consumption, compared to control | Attention, reaction time - assessed using computerized cognitive battery including RTI (reaction time) test. | ClinicalTrials.gov |
| Primary | Cognitive measures | Change from baseline at 1.5 hours post-dose, and 12 weeks daily consumption, compared to control | Global cognitive function - assessed by calculating a z-score from the cognitive battery score outcomes | ClinicalTrials.gov |
| Secondary | Circulating plasma biomarkers relating to cognitive function | Change from baseline at 1.5 hours post-dose, and 12 weeks daily consumption, compared to control | Brain derived neurotrophic factor (BDNF) | ClinicalTrials.gov |
| Secondary | Mood measurement | Change from baseline at 1.5 hours post-dose, and 12 weeks daily consumption, compared to control | assessed using SCAS (the Swedish Core Affect Scale) mood questionnaire. A validated self-report measure of affective state. The SCAS comprises of 12 affective states that subjects rate on a scale from 1 - 10. | ClinicalTrials.gov |
| Secondary | Self-reported quality of life | Difference from baseline vs control following 12 weeks of daily consumption | assessed using the quality of life scale from the EQ-5D (EuroQol 5 Dimension) self-report survey. The subject grades their current overall quality of life on a scale 0-100. | ClinicalTrials.gov |
| Secondary | Well-being measurement | Difference from baseline vs control following 12 weeks of daily consumption | Assessed with World Health Organization- Five Well-Being Index (WHO-5). A validated 5 item scale for self-reporting levels of perceived well-being over the last two weeks. Items are rated using a 5-point scale. | ClinicalTrials.gov |
| Secondary | Subjective memory | Difference from baseline vs control following 12 weeks of daily consumption | Assessed using 3 simple questions about the subject's own memory evaluation. The subject is asked to rate their memory function (scale 0 to 7), how they percieve their own memory is working compared to others in the same age (0 to 5) and if anyone close to them has expressed concern over the subjects' memory | ClinicalTrials.gov |
| Secondary | Cardiometabolic risk factor | Change from baseline at 1.5 hours post-dose, and 12 weeks daily consumption, compared to control | blood pressure (SBP) | ClinicalTrials.gov |
| Secondary | Cardiometabolic risk factor | Change from baseline at 1.5 hours post-dose, and 12 weeks daily consumption, compared to control | blood pressure (DBP) | ClinicalTrials.gov |
| Secondary | Cardiometabolic risk factor | Change from baseline at 1.5 hours post-dose, and 12 weeks daily consumption, compared to control | Heart rate (HR) | ClinicalTrials.gov |
| Secondary | Body composition | Change from baseline following 12 weeks daily consumption, compared to control | Body weight (kg) | ClinicalTrials.gov |
| Secondary | Body composition | Change from baseline following 12 weeks daily consumption, compared to control | Body mass index (BMI) (e.g., weight (kg) and height (m) will be combined to report BMI in kg/m\^2). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Paced Visual Serial Addition Test | Primary outcome | ConductCognition |
| Paired Associate Learning | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Verbal Fluency | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)